Nicholas Chasse
Nurse Practitioner · Lincoln, RINPI 1063991024
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 24.2% of the total. Reporting peaked in 2022 at $1,549 and has fallen 97.5% since, to $39 in 2025. Among nurse practitioner clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$833
- AstraZeneca$544
- Vanda Pharmaceuticals Inc.$469
- GSK$382
- Teva Pharmaceuticals USA, Inc.$217
- Nestle Healthcare Nutrition Inc.$197
- plus $799 from 16 others
What the payments were for
- Food & beverage$3,442100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $833 |
| AstraZeneca(2 entities) | 26 | $544 |
| Vanda Pharmaceuticals Inc. | 15 | $469 |
| GSK | 21 | $382 |
| Teva Pharmaceuticals USA, Inc. | 13 | $217 |
| Nestle Healthcare Nutrition Inc. | 10 | $197 |
| Mylan Specialty L.p. | 11 | $172 |
| Novo Nordisk | 6 | $125 |
| Amgen | 6 | $101 |
| Inspire Medical Systems, Inc. | 5 | $93 |
| Pfizer | 3 | $57 |
| Abbott | 2 | $34 |
| Acerus Pharmaceuticals Corporation | 2 | $28 |
| Johnson & Johnson | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Exact Sciences | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$3,442 in reported general payments places this provider in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,206 |
| FarxigaDapagliflozin Propanediol | 13 | $11,620 |
| Atorvastatin Calcium | 85 | $1,171 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $794 |
| Omeprazole | 47 | $755 |
| Ezetimibe | 15 | $632 |
| Lisinopril | 60 | $503 |
| Gabapentin | 30 | $482 |
| Rosuvastatin Calcium | 31 | $453 |
| Amlodipine Besylate | 68 | $439 |
| Levothyroxine Sodium | 40 | $430 |
| Losartan Potassium | 43 | $392 |
| Metformin Hcl ErMetformin Hcl | 32 | $343 |
| Tamsulosin Hcl | 16 | $330 |
| Fluticasone Propionate | 23 | $281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $382 | $12,20620 claims |
| AstraZenecaFarxiga | $544 | $11,62013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Other nurse practitioner in Lincoln
- Linda YoungLincoln$19K
- Ruth ChevezLincoln$2K
- Victoria VoshchinLincoln$409
- Lynne GlaserCumberland$17K
- Stephanie CostaWarwick$9K
- Maria SilvaJohnston$7K
- Natalie DriscollMiddletown$6K
- Lea KellyProvidence$5K
- Kathleen ParkerWarwick$5K
- Priscilla PonteEast Providence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.